Original Article

International study on low-grade primary central nervous system lymphoma†

  1. Kristoph Jahnke MD1,2,*,
  2. Agnieszka Korfel MD1,
  3. Brian Patrick O'Neill MD3,
  4. Jean-Yves Blay MD, PhD4,
  5. Lauren E. Abrey MD5,
  6. Peter Martus PhD6,
  7. Philip M. P. Poortmans MD, PhD7,
  8. Tamara N. Shenkier MD8,
  9. Tracy T. Batchelor MD9,
  10. Edward A. Neuwelt MD2,
  11. Jeffrey J. Raizer MD10,
  12. David Schiff MD11,
  13. Hendrik Pels MD12,
  14. Ulrich Herrlinger MD13,
  15. Harald Stein MD14,
  16. Eckhard Thiel MD1

Article first published online: 3 APR 2006

DOI: 10.1002/ana.20804

Issue

Annals of Neurology

Annals of Neurology

Volume 59, Issue 5, pages 755–762, May 2006

Additional Information

How to Cite

Jahnke, K., Korfel, A., O'Neill, B. P., Blay, J.-Y., Abrey, L. E., Martus, P., Poortmans, P. M. P., Shenkier, T. N., Batchelor, T. T., Neuwelt, E. A., Raizer, J. J., Schiff, D., Pels, H., Herrlinger, U., Stein, H. and Thiel, E. (2006), International study on low-grade primary central nervous system lymphoma. Annals of Neurology, 59: 755–762. doi: 10.1002/ana.20804

Author Information

  1. 1

    Departments of Hematology, Oncology and Transfusion Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

  2. 2

    Blood-Brain Barrier & Neuro-Oncology Program, Oregon Health & Science University, Portland, OR

  3. 3

    Neuro-Oncology Program, Mayo Clinic Cancer Center, Rochester, MN

  4. 4

    Unité Cytokines et Cancers, Centre Léon Berard & Hôpital E. Herriot, Lyon, France

  5. 5

    Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY

  6. 6

    Department of Biostatistics and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

  7. 7

    Dr Bernard Verbeeten Instituut, Tilburg, the Netherlands

  8. 8

    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada

  9. 9

    Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA

  10. 10

    Davee Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL

  11. 11

    Division of Neuro-Oncology, University of Virginia, Charlottesville, VA

  12. 12

    Department of Neurology, Knappschaftskrankenhaus Bochum-Langendreer, University of Bochum, Bochum, Germany

  13. 13

    Department of General Neurology, Center for Neurology, University of Tübingen, Tübingen, Germany

  14. 14

    Department of Pathology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

*Department of Hematology, Oncology and Transfusion Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, D-12200 Berlin, Germany

  1. †

    Members of the IPCG are listed in the ‡ on page 761.

Publication History

  1. Issue published online: 21 APR 2006
  2. Article first published online: 3 APR 2006
  3. Manuscript Accepted: 16 DEC 2005
  4. Manuscript Revised: 25 NOV 2005
  5. Manuscript Received: 24 AUG 2005

Funded by

  • German Cancer Aid (Deutsche Krebshilfe). Grant Number: 70-2838

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (151K)

Abstract

Objective

The aim of this study was to characterize the clinical presentation, course, and outcome of low-grade primary central nervous system lymphoma.

Methods

Cases were assessed in a retrospective series collected from 18 cancer centers in 5 countries.

Results

Forty patients (18 men, 22 women; median age, 60 years [range, 19–78]) were identified. Involvement of a cerebral hemisphere or deeper brain structures was seen in 37 patients, only leptomeningeal involvement in 2 patients, and spinal cord disease in 1 patient. Chemotherapy/radiotherapy was conducted in 15 patients, radiotherapy alone in 12, chemotherapy alone in 10, and tumor resection alone in 2, whereas 1 patient received no treatment. The median progression-free, disease-specific, and overall survival were 61.5 (range, 0–204), 130 (range, 1–204), and 79 (range, 1–204) months, respectively. Only age 60 years or older was associated with shorter progression-free (p = 0.009), disease-specific (p = 0.015), and overall survival (p = 0.001) in multivariate analysis.

Interpretation

Low-grade primary central nervous system lymphoma differs from the high-grade subtype in its pathological, clinical, and radiological features. It has a better long-term outcome than primary central nervous system lymphoma in general with age 60 years or older adversely affecting survival. Ann Neurol 2006

View Full Article (HTML) Get PDF (151K)